Refined testing and targeted therapy lead new fight against prostate cancer

William J. Catalona*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Prostate cancer screening and intervention remain controversial, despite significant strides in the detection and treatment of this common malignancy. False-positive results from the test for prostate specific antigen (PSA) lead to unnecessary workups and biopsies, as well as psychological stress for patients. Radical prostatectomy remains the most effective treatment for organ-confined cancer, yet many patients opt for the organ-sparing advantage of radiation therapy. Others may opt for unproven interventions such as cryoablation. Recently-developed tools designed for use with PSA testing are helping to improve screening accuracy in the lower tier of serum total PSA (2.5 to 10.0 ng/mL).

Original languageEnglish (US)
Pages (from-to)49-54
Number of pages6
JournalGeriatrics
Volume54
Issue number9
StatePublished - Jan 1 1999

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Fingerprint Dive into the research topics of 'Refined testing and targeted therapy lead new fight against prostate cancer'. Together they form a unique fingerprint.

Cite this